Taysha Gene Therapies/TSHA

$3.02

-6.5%
-
1D1W1MYTD1YMAX

About Taysha Gene Therapies

Taysha Gene Therapies, Inc. is a patient-centric gene therapy company. The Company is focused on developing and commercializing adeno-associated virus (AAV)-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS). Its portfolio of gene therapy candidates targets a range of neurological indications across three distinct therapeutic categories: neurodegenerative diseases, neurodevelopmental disorders, and genetic epilepsies. Its product candidates include TSHA-120, a clinical-stage, intrathecally dosed AAV9 gene therapy program for the treatment of giant axonal neuropathy (GAN); TSHA-102, a self-complementary intrathecally delivered AAV9 gene transfer therapy product candidate in clinical evaluation for Rett syndrome; TSHA-118, a self-complementary AAV9 viral vector that expresses human codon-optimized Ceroid Lipofuscinosis Neuronal 1 (CLN1) complementary deoxyribonucleic acid under control of the chicken b-actin hybrid promoter, and others.

Ticker

TSHA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Sean Nolan

Employees

65

Headquarters

Dallas, United States

TSHA Metrics

BasicAdvanced
$603.88M
Market cap
-
P/E ratio
-$2.58
EPS
0.29
Beta
-
Dividend rate

What the Analysts think about TSHA

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 9 analysts.
85.76% upside
High $7.50
Low $2.00
$3.02
Current price
$5.61
Average price target

TSHA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-2,489.36% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$4.7M
104.35%
Net income
$-117M
377.55%
Profit margin
-2,489.36%
133.7%

TSHA Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 438.51%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.99
-$0.28
-$0.38
-$0.93
-
Expected
-$0.33
-$0.35
-$0.31
-$0.17
-$0.11
Surprise
200.7%
-20.93%
22.14%
438.51%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Taysha Gene Therapies stock

Buy or sell Taysha Gene Therapies stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing